Alzheimer’s Drug Discovery Foundation: Neuroimaging and CSF Biomarker Program

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:
– Developing novel PET ligands for clinical trials
– Supporting novel CSF biomarkers
– Validating established MRI approaches in larger cohorts
– Veripheral biofluids and digital approaches are supported through the Diagnostics Accelerator RFP.

Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Other target areas of interest include:
– Neuronal loss
– Vascular injury and blood-brain barrier integrity
– Mitochondria and metabolic function
– Protein misfolding
– Oxidative stress
– White matter changes
– Lewy body dementia
– Other novel targets supported by compelling biological rationale and connection to disease